9P - Systematic determination of EGFR mutation (m) and immunohistochemistry (IHC) of ALK translocation (t) status in patients (p) with newly non small ce...
|Date||28 March 2014|
|Session||Lunch and poster display session|
|Topics|| Non-Small-Cell Lung Cancer, Metastatic
|Presenter||Santiago Ponce Aix|
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
S. Ponce Aix1, J. Zugazagoitia2, M. Blazquez Arroyo1, G. Ruiz Ares1, J.A. Nuñez Sobrino1, L.C. Iglesias Docampo1, R.A. Manneh Kopp1, R.M. García Martín3, J.L. Rodriguez Peralto3, A.B. Enguita Valls3
Detection of EGFR m. p. is done in a routine way. Also detection of ALK t. has become an important issue for therapeutic decision making in NSCLC. Which is the best technic to broad test of ALK t. remain unclear. We implemented a systematic determination of EGFR m. and ALK t. status to asses feasibility and accuracy in a clinical setting.